GlassScriptPhysician profile
Patricia S Gomez
NPI 1487639142
$1,576.53
in general payments reported to CMS, 2019-2025
22 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $197 · 2021: $194 · 2022: $268 · 2023: $272 · 2024: $121 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $232.37 | 2021-2025 | Farxiga, Airsupra |
| Sunovion Pharmaceuticals INC. | $189.98 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $155.31 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $152.85 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $137.52 | 2021-2025 | Evenity, Prolia |
| Canon Medical Systems USA, INC. | $89.49 | 2019 | |
| Ucb, INC. | $70.54 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $65.86 | 2023 | Aptiom |
| Gilead Sciences, INC. | $60.07 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $59.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.47 | 2019-2022 | |
| Exact Sciences Corporation | $40.24 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $35.57 | 2021-2025 | Kisunla |
| Eisai INC. | $32.63 | 2021-2022 | |
| Biogen, INC. | $31.01 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $28.74 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $26.98 | 2024 | |
| Acadia Pharmaceuticals INC | $25.72 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $24.09 | 2021-2022 | |
| Astellas Pharma US INC | $23.78 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.